309.394 ARS
4.17 T ARS
25.07 T ARS
About Johnson & Johnson
Sector
CEO
Joaquin Duato
Headquarters
New Brunswick
Website
Founded
1887
ISIN
ARDEUT110236
FIGI
BBG000C4WYM3
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
JNJ major support...must hold, buying a few shares here
the inverse head and shoulder failed, NYSE:JNJ is now close to the bottom of this multi-year flag...
it must hold or a bigger flush may occur, given the stability of the company, I am leaning towards a bounce and buying a few shares for the long term
no options till price close above the 9/21
Gamma peak on 145 indicating up direction Gamma peak on 145 indicating up direction , its demand and support area with MACD Histogram Divergence seen its supposed to go toward 148 in case 144/143 will hold
Technical Analysis of Johnson & Johnson Stock (JNJ)This chart for JNJ illustrates a technical setup within a descending channel. Key Fibonacci retracement levels (38.2%, 50%, and 61.8%) are highlighted, indicating potential zones of support and resistance. The analysis suggests a three-part buying strategy: an initial purchase at the current market
Johnson & Johnson | JNJ | Long at $146.00Johnson & Johnson NYSE:JNJ is strong (but highly controversial) company with anticipated earnings growth on the horizon. With a P/E of 23x, steady dividend growth record, low debt, and expected increased cashflow, the future is optimistic for NYSE:JNJ if they can stay out of the shady spotlight.
$JNJ Call verticalNYSE:JNJ has been declining for some time. Currently the bullish divergence is everywhere. The price is also outside the BB band. I think there is a very good change for the price to move up in the coming days.
I bought Jan. 2025 $150/$155 call vertical for $2.33
I will double my money if the stoc
JNJ Long consolidation..potential breakoutNYSE:JNJ has been consolidating for over 2 years on this range now:
* monthly bull flag
* forming the right shoulder of an IHS on weekly chart (can even see it on the monthly)
* healthcare sector oversold, so can see a bounce
a bounce could push JNJ to test the upper trendline at 165-166.
The IHS
$150 support for JNJ?$150 was a popular area from April to July. Once it finally broke through, it went to its high for the year of $168. Even after a good earning report, JNJ has been on the decline since. It hopefully found support at $150. It stayed in the support range for two days and immediately had the bullis
JNJThe JNJ stock is in a strong downtrend and has bounced back four times from it. We expect the stock to make a new low below $140, with a stop loss if it breaks above the last high at $167.
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where JNJ is featured.
